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OBJECTIVES This study was designed to assess the effects of spironolactone (SP) on left ventricular (LV)
function and exercise tolerance in patients with chronic heart failure (CHF).
BACKGROUND In severe heart failure (HF), SP improves survival, but the underlying mechanisms are not
clear.
METHODS We randomized 106 outpatients with HF to SP (12.5 to 50 mg/day) (group 1) or control
(group 2). Complete echocardiography and cardiopulmonary exercise testing were performed
at baseline and 12 months after randomization.
RESULTS Left ventricular end-systolic volume at baseline and at follow-up was 188 94 ml and 171
97 ml in group 1 and 173  71 ml and 168  79 ml in group 2 (treatment group-by-time
interaction, p 0.03). Left ventricular ejection fraction at baseline and at follow-up was 33
7% and 36 9% in group 1 and 34 7% and 34 9% in group 2 (treatment group-by-time
interaction, p  0.02). At baseline, 9 patients in group 1 and 3 patients in group 2 had a
restrictive mitral filling pattern, a marker of severe diastolic dysfunction; at follow-up, 3
patients in group 1 and no patient in group 2 improved their pattern. No patient in group 1
and 4 patients in group 2 worsened their pattern (chi-square, p  0.02). Peak oxygen
consumption increased significantly in patients treated with 50 mg of SP and decreased in
group 2 (17.7  5.2 vs. 18.5  5.9 and 19.1  5.6 vs. 17.9  5.3, respectively; analysis of
variance, p  0.01).
CONCLUSIONS Spironolactone improves LV volumes and function; furthermore, it improves exercise
tolerance at the highest administered dose. Our data might explain the mortality reduction
during aldosterone antagonism in patients with HF. (J Am Coll Cardiol 2002;40:304–10)
© 2002 by the American College of Cardiology Foundation
The modulation of neurohormonal activation in patients
with chronic heart failure (CHF) is one of the main goals in
the management of this condition. It has been shown that
the suppression of aldosterone production with angiotensin-
converting enzyme (ACE) inhibitors alone is not complete
(1); after an initial reduction, aldosterone levels subse-
quently rise in a variable percent of patients treated with
ACE inhibitors (2–4). This brings about important conse-
quences, as aldosterone stimulates collagen synthesis at the
myocardial level (5), therefore contributing to the alteration
of cardiac structure and function. Furthermore, we have
previously shown that elevated levels of aldosterone are
associated with impaired exercise tolerance in patients with
CHF (6).
The Randomized ALdactone Evaluation Study
(RALES) demonstrated a 30% reduction of mortality in
New York Heart Association (NYHA) functional class III
and IV patients treated with the aldosterone antagonist
spironolactone (SP) in addition to standard therapy for
CHF (7), but the underlying mechanisms for this are still
not clear. No previous randomized study analyzed the effects
of aldosterone antagonism on left ventricular (LV) function
and exercise capacity in a large population of patients with
CHF. Therefore, we aimed to assess whether SP adminis-
tration might improve LV function and exercise tolerance in
patients with CHF already receiving an ACE inhibitor.
Finally, we aimed to assess the effects of different doses of
SP on the response variables.
METHODS
Patients. Patients were eligible for enrollment if they had a
diagnosis of CHF and were in stable clinical condition for at
least six months, if they were on an ACE inhibitor at the
maximal tolerated dose and had a left ventricular ejection
fraction (LVEF) of no more than 45%. In order to obtain an
accurate evaluation of diastolic function, only patients in
sinus rhythm were included. Treatment with digitalis,
diuretics and beta-blockers was allowed, but potassium-
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sparing diuretics were not permitted. Patients were excluded
from the study if they had valvular heart disease, unstable
angina, recent myocardial infarction (6 months), active
cancer, renal failure (serum creatinine 150 mol/l), hy-
perkaliemia (serum potassium 5.0 mEq/l) or hepatic
failure. The local ethics committee approved the protocol
and every patient gave written informed consent before the
beginning of the study.
After an initial clinical evaluation, 106 patients were
randomized to SP treatment (n  54, group 1), at an initial
dose of 25 mg once daily or control group (n 52, group 2)
for 12 months. Follow-up evaluation was performed every
four weeks and included measurements of serum potassium
and creatinine. In the presence of normal potassium and
creatinine levels, the SP dose was titrated up to 50 mg once
daily. If hyperkaliemia developed, the dose of SP could be
adjusted to a minimum of 12.5 mg once daily. Study
medication could be withheld in the event of persistent
hyperkaliemia after dose adjustment, serum creatinine levels
of more than 200 mol/l or severe breast pain or gyneco-
mastia. At baseline and 12 months after randomization
every patient underwent a complete clinical and echocardio-
graphic evaluation, cardiopulmonary exercise testing and
assessment of neurohormonal activation. Venous blood
samples for hormonal measurements were obtained in a
fasting state, between 8 AM and 9 AM, after a 30-min supine
rest. The concentrations of aldosterone and renin were
measured by a sandwich radioimmunoassay (Biochem Im-
muno System, Rome, Italy) at the Laboratory of Clinical
Chemistry of our hospital. Norepinephrine was measured by
high performance liquid chromatography. The reference
values in our laboratory are 3.9 to 49.3 mU/l for renin, 215
to 475 pg/ml for norepinephrine and 0.1 to 0.42 nmol/l for
aldosterone.
Echocardiography. An echocardiographic evaluation was
performed in every patient before randomization and after
12 months of treatment by an operator blind to the
treatment group. Left ventricular end-diastolic and end-
systolic volumes and ejection fraction were measured from
apical four-chamber view using the monoplane area-length
method. Left atrial area was measured at end-systole (the
largest dimension) from an apical four-chamber view (area-
length method). Left atrial volume was calculated from the
left atrial area as previously reported (8).
Mitral flow velocities were recorded using an apical
four-chamber view, placing a 0.5 to 1.0 cm pulsed-wave
Doppler sample volume between the tips of the mitral
leaflets, where maximal velocity was recorded. E- and
A-wave velocities and their ratio (E/A) and A-wave dura-
tion were measured. Deceleration time of the E-wave was
measured as the interval from peak early mitral filling to an
extrapolation of the deceleration to 0 m/s. A restrictive
mitral filling pattern (RMFP), marker of severe diastolic
dysfunction (9), was defined as: 1) E/A ratio 2; or 2) E/A
ratio 1 and E-wave deceleration time 140 ms. Accord-
ing to the mitral filling pattern at follow-up compared with
baseline, three conditions were expected: 1) improvement, if
patients with a baseline RMFP had a reversal of the diastolic
filling; 2) unchanged RMFP; or 3) newly developed RMFP.
Cardiopulmonary exercise testing. Patients underwent a
symptom-limited bicycle ergometer exercise test at a con-
stant cadence of 60 rpm. The test was supervised and
interpreted by a physician blind to treatment group. A
continuous ramp protocol was used in which work rate was
increased by 10 W/min. Gas exchange was monitored
during the exercise test with a computerized metabolic cart
(SensorMedics, Vmax 229, Yorba Linda, California). Ox-
ygen uptake (VO2), carbon dioxide production (VCO2),
minute ventilation (VE) and respiratory exchange ratio were
measured online every 10 s using a standard inert gas
dilution technique. Peak VO2 was defined as the highest
VO2 achieved during exercise. The slope of the relation
between ventilation and carbon dioxide production (VE/
VCO2) was calculated from the exercise data and taken as an
index of the ventilatory response to exercise.
Statistical analysis. Data are expressed as mean  SD.
Time-sequence (between baseline and 12-month-follow-
up) changes and group comparisons were assessed by
repeated measure analysis of variance (ANOVA) models.
Additionally, comparisons within group between baseline
and 12 month-follow-up were made by Student t test for
paired data. Categorical data were compared by using a
chi-square test. Linear regression analysis was used to
determine the relations between variables. Commercially
available statistical software was used (Statview 5.0, Abacus
Concepts Inc; SAS 6.12, SAS Institute, Cary, North
Carolina). A p value 0.05 was considered statistically
significant.
RESULTS
A total of 106 patients were enrolled in the study: 54 were
assigned to SP treatment and 52 to control group. Of the
106 randomized patients, 13 did not undergo repeat clinical
and echocardiographic assessment for the following reasons:
7 patients because of death (3 in group 1, 4 in group 2), 2
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
ANOVA  analysis of variance
CHF  chronic heart failure
E/A  E-wave/A-wave ratio
HF  heart failure
LV  left ventricular
LVEF  left ventricular ejection fraction
NYHA  New York Heart Association
RALES  Randomized ALdactone Evaluation Study
RMFP  restrictive mitral filling pattern
SP  spironolactone
VE  minute ventilation
VCO2  carbon dioxide production
VO2  oxygen consumption
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patients in group 2 and 1 patient in group 1 because of
worsening HF and prolonged hospitalization and 3 patients
because of hyperkaliemia requiring withdrawal of the study
medication. The remaining 93 patients completed the 12
month-follow-up evaluation (47 patients in group 1 and 46
patients in group 2).
The mean SP dose was 31.1  15.6 mg/day. Spirono-
lactone was given at a dose of 25 mg/day in 22 patients and
was uptitrated to 50 mg/day in 16 patients. In the remaining
nine patients a dose of 12.5 mg/day was given. Gynecom-
astia was observed in two patients, but was well tolerated
and therefore the drug administration was not discontinued.
The clinical baseline characteristics of study population
are summarized in Table 1. Most patients were men and
had CHF of ischemic origin. The percentage of the maxi-
mally recommended dose of ACE inhibitor averaged 62 
36% in the whole population and 66  35% and 58  36%
in group 1 and group 2, respectively (p  NS). The
fruosemide dose was 47  52 mg in the whole population
and 42  36 mg and 52  36 mg in group 1 and group 2,
respectively (p  NS). The frequency of therapy with
beta-blockers was 69% and was similar in the two groups of
patients (72% vs. 65%, p  NS).
Plasma aldosterone levels at baseline and at follow-up
were 0.26  0.1 nmol/l and 0.38  0.5 nmol/l in group 1
and 0.26  0.1 nmol/l and 0.24  0.2 nmol/l in group 2
(p  0.05 for treatment group-by-time interaction); plasma
renin levels at baseline and at follow-up were 76.8 
86.9 mU/l and 231.7  259.9 mU/l in group 1 and 85.9 
110.7 mU/l and 108.7  207.4 mU/l in group 2 (p 
0.0055 for treatment group-by-time interaction). These
effects of SP reflect the loss of negative feedback inhibition
on the renin-angiotensin system. Plasma norepinephrine
levels at baseline and at follow-up were 385  284 pg/ml
and 452  194 pg/ml in group 1 and 371  224 pg/ml and
427  223 pg/ml in group 2 (treatment group-by-time
interaction, p  NS).
Echocardiography. Baseline and follow-up echocardio-
graphic characteristics of the study population are summa-
rized in Table 2. There was a significant reduction in LV
end-systolic volume and a borderline reduction in LV
end-diastolic volume in group 1 patients, whereas there
were no changes from baseline in group 2 patients (treat-
ment group-by-time interaction, p  0.03 and p  0.06,
respectively). At follow-up, the left atrial end-systolic vol-
ume significantly decreased in group 1 patients compared
with baseline (paired t test, p  0.01). Left ventricular
ejection fraction significantly improved in group 1 and did
not change in group 2 (treatment group-by-time interac-
tion, p  0.02).
Among the mitral flow Doppler parameters, a trend
versus improvement was seen for E/A ratio in group 1
patients and no significant changes were observed in group
2 (treatment group-by-time interaction, p  0.07). At
baseline, 9 patients in group 1 and three patients in group 2
had a RMFP; at follow-up, three patients in group 1 and no
patients in group 2 improved their pattern; no patients in
group 1 and 4 patients in group 2 worsened their pattern
(chi-square test, p  0.02).
Table 1. Clinical Variables of Study Population at Baseline
Total
Population
(n  106)
Control
Group
(n  52)
Spironolactone
(n  54)
NYHA functional class 2.2  0.7 2.1  0.7 2.3  0.7
Gender (male/female) 92/14 46/6 46/8
Age (yrs) 62.1  8.3 61.7  9.8 62.5  7.9
Etiology
Idiopathic n (%) 38 (36) 19 (37) 19 (35)
Ischemic n (%) 68 (64) 33 (63) 35 (65)
BMI (kg/m2) 26.9  4.1 27.1  4.1 26.8  4.0
S-Sodium (mEq/l) 139  3 139  2 139  3
S-Potassium (mEq/l) 4.3  0.3 4.3  0.4 4.3  0.3
S-Creatinine (mol/l) 98.7  25.3 100.0  31.1 96.3  19.2
Max. ACE inhibitor
dose (%)
62  36 58  36 66  35
Frusemide dose (mg) 47  52 52  36 42  36
Beta-blockers, n (%) 73 (69) 34 (65) 39 (72)
Data are expressed as mean  SD or number (%).
ACE inhibitor dose  percentage of maximally recommended angiotensin-
converting enzyme inhibitor; BMI  body mass index; NYHA  New York Heart
Association.
Table 2. Echocardiographic Characteristics of Study Population at Baseline and 12 Months
After Randomization
Variable
Control Group
(n  46)
Spironolactone
(n  47) p Value
(Repeated-Measures
ANOVA)Baseline Follow-Up Baseline Follow-Up
LVEDV (ml) 257  80 253  89 275  104 251  105* 0.06
LVESV (ml) 173  71 168  79 188  94 171  97* 0.03
LVEF (%) 34  7 34  9 33  7 36  9* 0.02
LAmax (ml) 99  34 95  34 102  38 89  36* NS
E max (m/s) 0.61  0.20 0.62  0.22 0.62  0.21 0.59  0.21 NS
A max (m/s) 0.72  0.22 0.69  0.19 0.65  0.19 0.68  0.18 NS
E/A ratio 1.1  1.3 1.0  0.72 1.2  1.0 0.94  0.64 0.07
DtE (ms) 220  69 214  88 217  93 219  67 NS
Symbols refer to Student t test for paired data. *p  0.01 vs. baseline.
A maxmitral A-wave velocity; ANOVA analysis of variance; DtE E-wave deceleration time; E maxmitral E-wave
velocity; LAmax  left atrial end-systolic volume; LVEDV  left ventricular end-diastolic volume; LVEF  left ventricular
ejection fraction; LVESV  left ventricular end-systolic volume.
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Exercise capacity. Table 3 summarizes the results of the
exercise variables at baseline and at follow-up in the two
groups of patients. Peak VO2 significantly decreased in
group 2 patients compared with baseline (t test for paired
data, p  0.001) and did not change in group 1 patients
(treatment group-by-time interaction, p  0.05). Absolute
peak VO2 showed similar changes. There was a trend
towards a decreased VE/VCO2 slope in group 1, but this did
not reach a statistically significant difference. Exercise time,
percent predicted peak VO2 and respiratory gas exchange
ratio did not significantly change in the two groups. The
absolute changes of LVEF from baseline showed a signifi-
cant, but weak, relation with the absolute changes of peak
VO2 from baseline (p  0.05, r  0.23).
Dose-dependent effect of SP. In order to assess whether
the SP dose might have an effect on the response variables,
we performed an ANOVA analysis and found a dose-
dependent effect on LVEF (p  0.05) and peak VO2
(0.05), as represented in Figure 1, with the greatest
benefits from SP in those patients treated with 50 mg of the
drug. The increase in plasma renin levels was highest in the
group of patients treated with 50 mg of SP compared with
the group of patients treated with a lower dose (p  0.05)
(Fig. 1).
DISCUSSION
In the present study we found a significant improvement in
LV volumes, systolic function and a trend versus improve-
ment of diastolic function after 12 months of treatment with
SP in ambulatory patients with CHF already on standard
treatment for this condition. The effect of SP on LV systolic
function was dose-dependent, with the greatest benefits in
the group treated with 50 mg of the drug. Furthermore,
there was a significant improvement in exercise capacity in
the group of patients treated with the highest dose of the
drug, whereas there was a significant reduction in peak VO2
in the control group. Our results suggest that SP adminis-
tration has important beneficial effects also in patients with
mild to moderate CHF, particularly at higher doses.
SP and LV function. Failure of aldosterone suppression
during ACE inhibitor therapy carries important conse-
quences in patients with CHF. It has been shown that
aldosterone is the hormone most closely associated with a
poor outcome in this condition (10). Furthermore, the
RALES trial has demonstrated a 30% reduction in mortality
in patients with severe CHF already receiving an ACE
inhibitor (7). There are several mechanisms potentially
contributing to the beneficial effects of aldosterone antago-
nism in patients on standard therapy for CHF. Aldosterone
promotes fluid retention (11) and alters electrolyte balance
(12); furthermore, it potentiates the effects of cat-
echolamines (13) and determines baroreflex dysfunction
(14). Another negative effect of aldosterone is represented
by collagen deposition at the myocardial level. The aldoste-
rone receptor is expressed in the myocardium (15), thus
representing the prerequisite for local effects of this hor-
mone. Furthermore, it has been shown that aldosterone
production is increased in the failing heart (16). These
observations might help to explain the effects of aldosterone
antagonism in patients with nonischemic dilated cardiomy-
opathy (17) and ischemic heart disease (18,19). Tsutamoto
et al. (17) have shown a positive effect on cardiac remodel-
ing, LV systolic function and mass in a small population of
CHF secondary to idiopathic dilated cardiomyopathy
treated with a fixed dose of 25 mg of SP for four months.
We found similar results in terms of LV volumes and
LVEF. Furthermore, we studied the effects of SP adminis-
tration on diastolic function. We observed an improvement
in LV filling pattern only in patients treated with SP, and a
worsening of the pattern during follow-up only in the
control group patients. When considering the markers of
diastolic dysfunction as continuous variables, we found only
a borderline effect for the E/A ratio. This might be due to
the low number of patients with marked diastolic dysfunc-
tion in our population together with the complex mecha-
nisms determining mitral inflow parameters (20), besides
diastolic dysfunction (21). We also observed a significant
decrease in left atrial volume in the treated group; this also
Table 3. Exercise Variables of Study Population at Baseline and 12 Months
After Randomization
Variable
Control Group
(n  46)
Spironolactone
(n  47) p Value
(Repeated Measures
ANOVA)Baseline Follow-Up Baseline Follow-Up
Peak VO2 (ml/min/kg) 18.5  5.5 17.8  5.3† 16.4  4.8 16.8  4.9 0.05
Absolute pVO2 (ml/min) 1503  548 1407  504* 1279  466 1269  466 NS
% Predicted pVO2 69  18 70  19 63  19 64  18 NS
RR 1.2  0.1 1.2  0.1 1.1  0.1 1.2  0.1 NS
Exercise time (min) 9.9  2.2 10.0  2.2 9.5  2.1 9.6  2.3 NS
VE/VCO2 slope 36.5  6.9 35.9  6.0 37.4  7.5 35.1  5.6 NS
Heart rate (beats/min) 76  18 72  13 71  12 72  13 NS
SBP (mm Hg) 137  27 131  24 134  17 128  21 NS
DBP (mm Hg) 88  15 85  11 80  11 81  10 NS
Data are expressed as mean SD. Symbols refer to Student t test for paired data. *p 0.01 vs. baseline; †p 0.001 vs. baseline.
ANOVA analysis of variance; DBP  diastolic blood pressure; RR  respiratory gas exchange ratio; SBP  systolic blood
pressure; VE/VCO2  relation of the minute ventilation to carbon dioxide production; VO2  oxygen consumption.
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indirectly supports an improvement on LV diastolic func-
tion (22).
As the composition of the extracellular matrix is an
important determinant of cardiac volumes and mechanics
(23,24), the improvement in LV volumes and both systolic
and diastolic function might be linked to the reduction in
myocardial fibrosis through SP, as previously reported both
in animal (25) and human (26,27) studies. A recent paper by
Zannad et al. (28) showed a marked reduction in serum
levels of markers of cardiac fibrosis in patients treated with
SP. Left ventricular systolic and diastolic dysfunction are
important prognostic markers in patients with CHF (29–
31); therefore, one mechanism leading to the mortality
reduction during aldosterone antagonism in CHF might be
due to the improvement in LV function.
SP and exercise capacity. The modulation of the neuro-
hormonal activation can improve exercise tolerance in pa-
tients with CHF. This has been already demonstrated both
for ACE inhibitors, alone or in association with angiotensin
II receptor blockers (32,33), and for beta-blockers (34).
Thus, in the presence of optimal therapy for CHF, few
adjunctive effects from SP would be expected on exercise
capacity. Surprisingly, we found a small but significant
improvement in peak VO2 in the group of patients treated
with 50 mg of SP. On the other hand, in the control group
there was a significant reduction in exercise capacity at
follow-up compared with baseline, reflecting the natural
history of the disease. This underlines the importance of
maximal neurohormonal antagonism at different levels.
The mechanisms underlying these effects of aldosterone
antagonism on exercise capacity might be found both in the
heart and in the periphery. We found a significant correla-
tion between the absolute changes in LVEF and in peak
VO2 from baseline; nevertheless, there was a wide range of
variation, and therefore only a small part of the changes in
peak VO2 can be attributed to central factors. We have
previously shown that elevated levels of aldosterone are
associated with impaired exercise tolerance and that this
effect is not due to the resting hemodynamics (6). Recently,
a randomized, placebo-controlled trial on the vascular ef-
fects of SP clearly showed a marked improvement in
endothelial function and a reduction in angiotensin I/an-
giotensin II conversion in CHF patients after treatment
(35). These effects might also contribute to a better vasodi-
lator capacity during exercise and therefore to an increased
exercise tolerance.
Interaction with other drugs. Previous studies on SP in
CHF were conducted in patients with standard therapy for
this condition, which did not include, at the time of the
RALES, the use of beta-blockers in NYHA functional class
III and IV patients. In another study (17), only 73% of
patients were receiving an ACE inhibitor, and only a small
proportion of patients were receiving a beta-blocker; there-
fore it might be argued that the concomitant use of ACE
inhibitors and beta-blockers might blunt the effects of SP.
In our study, chronic therapy with ACE inhibitors repre-
sented an inclusion criterion and 69% of patients were
already treated with beta-blockers at randomization. There-
fore, even during optimal therapy for CHF there is enough
residual aldosterone production to be blocked by aldoste-
rone receptor antagonism. This is indirectly confirmed by
the fact that there was a dose-dependent effect of SP on LV
function, exercise capacity and neurohormonal activation.
Study limitations. The present study has several limita-
tions. First, we hypothesize that the effects of SP on LV
function might be linked to a reduction in myocardial
fibrosis, but we did not measure serum collagen levels;
nevertheless, Zannad et al. (28) have demonstrated a sig-
nificant reduction in serum procollagen type III levels
Figure 1. Dose-dependent effects of spironolactone on left ventricular
ejection fraction (LVEF), peak oxygen consumption (PVO2) and plasma
renin levels in patients with chronic heart failure treated with 25 mg and 50
mg of the drug and in the control group. Variables are expressed as absolute
differences from follow-up and baseline evaluation.
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during aldosterone antagonism. Second, our population
does not represent that of the RALES trial, which included
patients with severe CHF; consequently, we can only
hypothesize that the mortality reduction during SP treat-
ment might be due to an improvement in LV function. On
the other hand, in patients with more severe CHF, charac-
terized by a more pronounced neurohormonal activation,
the effects of SP on cardiac function might be even more
striking. Last, we randomized patients to treatment and to
control group. Nevertheless, the absence of the placebo in
the present study represents only a minor limitation, because
the response variables were objective and have been evalu-
ated by physicians blind to the treatment group.
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